Biden Turns Up Pressure on Democrats Balking at Spending Bill
(Bloomberg) -- President Joe Biden ratcheted up pressure on congressional Democrats on Thursday, as discord within the party threatened to derail key pieces of his economic agenda, including lowering prescription drug prices and some of his proposed tax hikes on the wealthiest Americans.
“For a long time, this economy's worked great for those at the very top,” Biden said in a speech Thursday at the White House. “This our moment to deal working people back into the economy.”
Biden faulted Republicans for attacking his plan, but his remarks were aimed to unite Democrats around the struggles of middle class families. The president highlighted the prices of prescription drugs, hearing aids, gas, meat and high-speed internet, as well as the general costs of raising a child.
The recent back-and-forth on Capitol Hill has shown the limits of Biden's power to guide the $3.5 trillion plan through a narrowly divided Congress. Moderate Democrats have balked at recent efforts to negotiate on drug prices and to impose a new tax on the assets of the wealthiest people, measures that progressives applaud.
The White House can only afford to lose the support of three House Democrats for the package to pass; it needs all Democratic votes in the Senate.
On Wednesday, Biden hosted two moderate Democratic senators -- Joe Manchin of West Virginia and Kyrsten Sinema of Arizona -- for separate meetings at the White House. Manchin has pushed for a spending package less than half of Biden's proposal, a move that risks delaying the president's package by weeks or months in Congress with tax, health care and other issues still unresolved.
Biden's Economic Plan at Risk of Delays Amid Democratic Rifts
White House aides have spent the last several days negotiating and speaking with lawmakers and top staffers to weigh various options to raise enough money to fully fund Biden's plan and ensure as many big policies as possible survive the legislative process.
“That isn't about raising your taxes,” said Biden. “It's about the super wealthy finally beginning to pay what they owe.”
Progressives have been disappointed as House Democratic lawmakers shied away from ideas like taxing the increase of wealthy people's assets at death -- a key pillar of Biden's attempts to reduce income inequality. Just this week, after intense lobbying from the health-care industry, a handful of moderate Democrats also backed away from efforts to negotiate lower prescription drug prices.
Democratic Representatives Kurt Schrader of Oregon, Scott Peters of California and Kathleen Rice of New York joined Republicans in voting against a bill to allow the government to demand lower prices from drugmakers and cap price increases on some medicines. The measure failed to advance, in a tied committee vote.
©2021 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.